Off-label use of antipsychotics: are we mad? (Q36945015)

17 August 2017

1 reference

title

Off-label use of antipsychotics: are we mad? (English)

1 reference

17 August 2017

Camilla Haw

1

1 reference

17 August 2017

Jean Stubbs

series ordinal

2

1 reference

17 August 2017

language of work or name

English

0 references

publication date

1 September 2007

1 reference

Expert Opinion on Drug Safety

17 August 2017

published in

1 reference

17 August 2017

volume

6

1 reference

17 August 2017

issue

5

1 reference

17 August 2017

page(s)

533-545

1 reference

Off-label prescribing among office-based physicians

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.533

From clinical trials to real-world practice: use of atypical antipsychotic medication nationally in the Department of Veterans Affairs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.533

Antipsychotic prescribing pattern among Italian general practitioners: a population-based study during the years 1999-2002.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.533

Off-label use of antipsychotic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.533

Factors associated with antipsychotic drug use in residential care: changes between 1990 and 1997.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.533

Antipsychotic use in the elderly: shifting trends and increasing costs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.533

Why and how antipsychotic drugs are used in 40 Sydney nursing homes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.533

Prevalence and patterns of psychotropic and anticonvulsant medication use in children and adolescents referred to residential treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.533

Prescribing practices of outpatient child psychiatrists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.533

Psychotropic medication in children: a study from the Netherlands

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.533

Antipsychotic drugs for non-psychotic patients: assessment of the benefit/risk ratio in generalized anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.533

Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.533

Olanzapine augmentation of fluoxetine for refractory generalized anxiety disorder: a placebo controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.533

A review of antipsychotics in the treatment of obsessive compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.533

Antipsychotic augmentation of serotonergic antidepressants in treatment-resistant obsessive-compulsive disorder: a meta-analysis of the randomized controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.533

Antipsychotic augmentation for treatment resistant obsessive-compulsive disorder: what if antipsychotic is discontinued?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.533

Review: antidepressant plus antipsychotic increases clinical response rates in psychotic depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.533

Psychotic major depression: a benefit-risk assessment of treatment options

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.533

Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines. British Association for Psychopharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.533

The role of atypical antipsychotics in bipolar depression and anxiety disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.533

A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.533

Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.533

National trends in the outpatient treatment of children and adolescents with antipsychotic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.533

Metabolic side effects of atypical antipsychotics in children: a literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.533

Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.533

CSM warning on atypical psychotics and stroke may be detrimental for dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.533

Atypical antipsychotic drugs and risk of ischaemic stroke: population based retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.533

Risk of death in elderly users of conventional vs. atypical antipsychotic medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.533

Antipsychotic drug use and mortality in older adults with dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.533

A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.533

Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.533

A double-blind randomised comparison of risperidone and haloperidol in the treatment of behavioural and psychological symptoms in Chinese dementia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.533

Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.533

Aripiprazole in the treatment of patients with borderline personality disorder: a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.533

Prescribing of potentially harmful drugs to patients admitted to hospital after head injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.533

Methotrimeprazine in the treatment of agitation in acquired brain injury patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.533

Managing agitation and aggression after head injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.533

Evidence-based practices in intellectual disability and behaviour disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.533

Uses of clozapine in nonschizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.533

Childhood-onset schizophrenia. A double-blind clozapine-haloperidol comparison

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.533

The off-label use of clozapine in adolescents with bipolar disorder, intermittent explosive disorder, or posttraumatic stress disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.533

The use of high-dose antipsychotic medication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.533

High dose antipsychotic use in schizophrenia: findings of the REAP (research on east Asia psychotropic prescriptions) study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.533

The safety and tolerability of atypical antipsychotics in bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.533

Psychotropic drug use in older people with mental illness with particular reference to antipsychotics: a systematic study of tolerability and use in different diagnostic groups.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.533

Adverse metabolic effects associated with atypical antipsychotics: literature review and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.533

Atypical antipsychotics and weight gain--a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.533

Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY). Part I: a review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.533

Drugs and falls in older people: a systematic review and meta-analysis: I. Psychotropic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.533

Atypical antipsychotic medications and risk of falls in residents of aged care facilities

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.533

Antipsychotic drugs and QT prolongation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.533

Off-label and non-classical prescriptions of antipsychotic agents in ordinary in-patient practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.533

Prescribing practices of community child and adolescent psychiatrists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.533

Trends in the Use of Typical and Atypical Antipsychotics in Children and Adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.533

21 January 2018

Identifiers

DOI

10.1517/14740338.6.5.533

1 reference

17 August 2017

1 reference